Congratulations to Alebund Pharmaceuticals (Jiangsu) Limited（9637.HK） on its successful Listing on the Mainboard of HKSE on 29 June 2026.

Alebund Pharmaceuticals (Jiangsu) Limited (the “Alebund”) is a biopharmaceutical company providing renal therapies. Alebund’s product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate (AP306), one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307) as of the Latest Practicable Date.

With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services on financial instruments, financial assets and property valuation.

Congratulations again Alebund Pharmaceuticals (Jiangsu) Limited（9637.HK） on its successful listing. The issue price of the shares is HKD 22.6 per share, and the amount of funds raised is HKD 1.2827 billion.